Rates of HCV-related decompensated cirrhosis and liver-related mortality have decreased in New South Wales since direct-acting antiviral (DAA) therapy became available. The evidence for longer-term benefit beyond sustained virological response (SVR) should further encourage efforts to boost uptake of the antivirals, say researchers from the Kirby Institute, Sydney. They note that about 24% of the ...
Already a member?
Enter your email to keep reading.